© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 7, 516-525,
April 4, 2001
© 2001 Oxford University Press
Effects of Retinoids on Cancerous Phenotype and Apoptosis in Organotypic Cultures of Ovarian Carcinoma
Affiliations of authors: S. Guruswamy, D. M. Benbrook (Departments of Obstetrics and Gynecology and Biochemistry and Molecular Biology), S. Lightfoot (Department of Pathology), M. A. Gold, R. T. Ivey (Department of Obstetrics and Gynecology), R. Hassan (Department of Medicine), University of Oklahoma Health Sciences Center, Oklahoma City; K. D. Berlin, Department of Chemistry, Oklahoma State University, Stillwater.
Correspondence to: Doris M. Benbrook, Ph.D., Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, P.O. Box 26901, Rm. WP2470, Oklahoma City, OK 73190. (e-mail: Doris-Benbrook{at}ouhsc. edu).
Background: Retinoic acid analogues, called retinoids, have shown promise in clinical trials in preventing breast and ovarian cancers. Classic retinoids bind to retinoic acid receptors, which regulate cell growth. Some novel retinoids, such as fenretinide, i.e., N-(4-hydroxyphenyl)retinamide (4-HPR), induce apoptosis through retinoic acid receptor-independent mechanisms; however, they appear to do so only at concentrations above those achieved in clinical chemoprevention trials. At lower concentrations (
1 µM), 4-HPR acts like classic retinoids, by inducing differentiation through a receptor-dependent mechanism. Our goal was to compare the effects of novel receptor-independent (apoptotic) retinoids with those of classic growth-inhibitory retinoids at clinically achievable doses on growth, differentiation, and apoptosis in ovarian tissue. Methods: Four receptor-independent (apoptotic) and seven growth-inhibitory retinoids, including synthetic, low-toxicity compounds called heteroarotinoids, were administered at concentrations of 1 µM to organotypic cultures of ovarian primary and cancer cell lines: OVCAR-3, Caov-3, and SK-OV-3. After fixation, embedding, and sectioning, the growth fraction was quantified by measuring expression of the proliferation marker Ki-67/myb, differentiation was assessed by expression of mucin, and apoptosis was evaluated by the TUNEL assay. Spearman correlation analysis was performed on the data, and all P values were two-sided. Results: All 11 retinoids reversed characteristics associated with the cancerous phenotype in all neoplastic cultures. Glandular structures were observed consistently in retinoid-treated, but not in untreated, OVCAR-3 and Caov-3 cultures. All retinoids decreased growth fractions, and some increased mucin expression. All receptor-independent retinoids and two receptor-dependent retinoids induced apoptosis, and the induction correlated significantly with increased expression of the mucin MUC1 (r = .83; P = .03). Retinoids with ester-linking groups did not induce apoptosis but decreased the growth fraction in correlation with MUC1 induction (r = -.93; P = .02). Conclusions: At clinically achievable concentrations, all retinoids tested decrease the growth fraction, induce differentiation and apoptosis. Induction of MUC1 expression is implicated in the mechanisms of action.
This article has been cited by other articles:
![]() |
Y.-D. Lin, S. Chen, P. Yue, W. Zou, D. M. Benbrook, S. Liu, T. C. Le, K. D. Berlin, F. R. Khuri, and S.-Y. Sun CAAT/Enhancer Binding Protein Homologous Protein-Dependent Death Receptor 5 Induction Is a Major Component of SHetA2-Induced Apoptosis in Lung Cancer Cells Cancer Res., July 1, 2008; 68(13): 5335 - 5344. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Elberg, D. Elberg, T. V. Lewis, S. Guruswamy, L. Chen, C. J. Logan, M. D. Chan, and M. A. Turman EP2 receptor mediates PGE2-induced cystogenesis of human renal epithelial cells Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1622 - F1632. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Liu, B. Hannafon, L. Gill, W. Kelly, and D. Benbrook Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria Mol. Cancer Ther., June 1, 2007; 6(6): 1814 - 1822. [Abstract] [Full Text] [PDF] |
||||
![]() |
P M Chiu, H C Feng, D M Benbrook, H Y S Ngan, U S Khoo, W C Xue, S W Tsao, K W Chan, and A N Y Cheung Effect of all-trans retinoic acid on tissue dynamics of choriocarcinoma cell lines: an organotypic model J. Clin. Pathol., August 1, 2006; 59(8): 845 - 850. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Shishodia, A. M. Gutierrez, R. Lotan, and B. B. Aggarwal N-(4-Hydroxyphenyl)Retinamide Inhibits Invasion, Suppresses Osteoclastogenesis, and Potentiates Apoptosis through Down-regulation of I{kappa}B{alpha} Kinase and Nuclear Factor-{kappa}B-Regulated Gene Products Cancer Res., October 15, 2005; 65(20): 9555 - 9565. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-i. Fukumoto, N. Yamauchi, H. Moriguchi, Y. Hippo, A. Watanabe, J. Shibahara, H. Taniguchi, S. Ishikawa, H. Ito, S. Yamamoto, et al. Overexpression of the Aldo-Keto Reductase Family Protein AKR1B10 Is Highly Correlated with Smokers' Non-Small Cell Lung Carcinomas Clin. Cancer Res., March 1, 2005; 11(5): 1776 - 1785. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Ferrari, M. Morini, U. Pfeffer, S. Minghelli, D. M. Noonan, and A. Albini Inhibition of Kaposi's Sarcoma in Vivo by Fenretinide Clin. Cancer Res., December 1, 2003; 9(16): 6020 - 6029. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-H. Chun, D. M. Benbrook, K. D. Berlin, W. K. Hong, and R. Lotan The Synthetic Heteroarotinoid SHetA2 Induces Apoptosis in Squamous Carcinoma Cells through a Receptor-independent and Mitochondria-dependent Pathway Cancer Res., July 1, 2003; 63(13): 3826 - 3832. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. A. Mic, A. Molotkov, D. M. Benbrook, and G. Duester Retinoid activation of retinoic acid receptor but not retinoid X receptor is sufficient to rescue lethal defect in retinoic acid synthesis PNAS, June 10, 2003; 100(12): 7135 - 7140. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Brewer, K. Johnson, M. Follen, D. Gershenson, and R. Bast Jr. Prevention of Ovarian Cancer: Intraepithelial Neoplasia Clin. Cancer Res., January 1, 2003; 9(1): 20 - 30. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Hassan, M. R. Lerner, D. Benbrook, S. A. Lightfoot, D. J. Brackett, Q.-C. Wang, and I. Pastan Antitumor Activity of SS(dsFv)PE38 and SS1(dsFv)PE38, Recombinant Antimesothelin Immunotoxins against Human Gynecologic Cancers Grown in Organotypic Culture in Vitro Clin. Cancer Res., November 1, 2002; 8(11): 3520 - 3526. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Montesano and P. Soulie Retinoids induce lumen morphogenesis in mammary epithelial cells J. Cell Sci., January 12, 2002; 115(23): 4419 - 4431. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Veronesi and A. Decensi Retinoids for Ovarian Cancer Prevention: Laboratory Data Set the Stage for Thoughtful Clinical Trials J Natl Cancer Inst, April 4, 2001; 93(7): 486 - 488. [Full Text] [PDF] |
||||







